Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]